Ben-Betzalel G, et al. - Researchers compared the efficacy and toxicity of anti–programmed cell death-1 (PD-1) therapy in ages 80–100 years vs ages 65–79 years in a cohort of 144 patients ≥65 years. They restrospectively obtained records of patients and analyzed baseline parameters, response rate (overall response rate [ORR]), best response, progression-free survival (PFS) and overall survival (OS) and immune-related adverse events. Between 2013 and 2018, a total of 500 patients received anti–PD-1 agents. two groups were defined: group A with 82 patients aged 65–79 years (median 71.5 years) and group B with 62 patients aged 80–100 years (median 84 years, range 80–97 years). Except for worse PS in group B, other baseline parameters were comparable. They analyzed response in 124 patients (76 group A, 48 group B). Findings revealed an enhanced response to anti–PD-1 therapy in elderly patients. An even better response to therapy and comparable survival in patients of very old age could be predicted by increasing age within the elderly patients group.